Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.